ArticleDiscover oncology2025
B7-H3: a promising target for immunotherapy in glioma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- B7-H3 (CD276) and CD47 Expression Are Associated with Immune Evasion and Survival Outcomes in Pediatric Medulloblastoma.Diagnostics (Basel, Switzerland) · 2026Article
- Harnessing γδ T cells for B7-H3-targeting CAR therapy to enhance anti-tumor therapy in glioblastoma.Journal of translational medicine · 2026Article
- Chimeric antigen receptor macrophages therapy for glioblastoma: challenges and opportunities from preclinical evidence to clinical translation.Frontiers in immunology · 2026Review
- Therapy-induced androgen receptor signaling as a candidate upstream driver of B7-H3-linked immune exclusion in melanoma: mechanisms and translational opportunities.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glioma is one of the most malignant tumors in the brain, with high tumor heterogeneity. Traditional treatment methods, such as surgery, radiotherapy and chemotherapy, face numerous challenges and still pose serious threats to human health. Therefore, it is urgent to explore new treatment directions. The immune checkpoint B7-H3 has attracted much attention due to its significant immunomodulatory function in various cancers. Studies have shown that it is highly expressed in glioma and lowly expressed in normal brain tissue. It not only has immunosuppressive function and induces immune escape in glioma, but also promotes the proliferation, migration and angiogenesis of glioma cells. Moreover, there are many immunotherapy strategies targeting B7-H3, such as monoclonal antibodies, antibody-drug conjugates (ADC) and chimeric antigen receptor T-cell (CAR-T) therapy. Therefore, B7-H3 is regarded as a potential target for glioma immunotherapy. This article systematically reviews the occurrence and development process of B7-H3 in glioma, changes in the immune microenvironment, and related treatment methods. Through analysis of several databases such as TCGA, CTPAC, HPA and GEPIA, this study explores the expression of B7-H3 in glioma, its correlation with prognosis and its correlation with the glioma immune microenvironment, providing a new research target for the diagnosis and treatment of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.